P53、EGFR、VEGF在胶质母细胞瘤的研究进展  

The Research Progress of P53, EGFR, VEGF in Glioblastoma

作　　者：孙立伟[1] 姜镕[1] 李金铎[1] 王斌[1] 马春华[1] 吕远[1] 穆宁[1] 

机构地区：[1]天津市环湖医院肿瘤介入科/天津市脑血管与神经变性重点实验室,天津300050

出　　处：《继续医学教育》2017年第11期86-89,共4页Continuing Medical Education

摘　　要：胶质母细胞瘤(glioblastoma,GBM)在世界范围内,是成人最常见且恶性程度最高的原发性脑肿瘤。尽管手术、常规放射治疗、化疗治疗,甚至三者联合治疗,均取得较大的进展,但是患者生存期仍未见明显提高。随着现代分子生物学和分子遗传学的发展,人们对胶质母细胞瘤的发病机制和诊断治疗的研究已经进入基因水平。目前P53基因、血管内皮生长因子(VEGF)、表皮生长因子受体(EGFR)是肿瘤研究的热点,它们在肿瘤发生、发展中起到不同的作用,为我们在GBM的靶向治疗中提供了方向。现就这三种基因在胶质母细胞瘤中表达情况、作用及以这三种基因为靶点的靶向治疗情况作以综述。Glioblastoma（GBM） is the most common and most malignant in intracranial primary tumors with poor prognosis in adults in the world. Despite surgery and radiation therapy has also made great progress in GBM, and even the combined treatment, the survival period is not obviously increased. With the development of molecular biology and molecular genetics, the pathogenesis, the diagnosis and treatment of glioblastoma has entered the genetic level. A growing number of studies have found that some genes, receptors, signal transduction pathways and signal conditioning molecules with glioblastoma are closely related to the occurrence and development, and it is possible that new solutions of glioblastoma treatment- molecular targeted therapy. At present, the genes of P53, VEGF and EGFR are hotspots of research on cancer, they play a different role in tumorigenesis and development, and provide the direction in GBM targeted drug therapy for us. This paper introduces the expression and effect of the three genes in GBM and target therapy with them as targets in GBM in recent years.

关 键 词：胶质母细胞瘤 P53基因 血管内皮生长因子 表皮生长因子受体 靶向治疗 

分 类 号：R739.4[医药卫生—肿瘤]